nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—S100B—artery—systemic scleroderma	0.041	0.122	CbGeAlD
Olopatadine—S100B—blood vessel—systemic scleroderma	0.0319	0.0952	CbGeAlD
Olopatadine—S100A2—Validated transcriptional targets of TAp63 isoforms—GDF15—systemic scleroderma	0.024	0.251	CbGpPWpGaD
Olopatadine—S100A1—connective tissue—systemic scleroderma	0.0189	0.0565	CbGeAlD
Olopatadine—S100A2—skin of body—systemic scleroderma	0.0186	0.0554	CbGeAlD
Olopatadine—S100A2—p73 transcription factor network—GDF15—systemic scleroderma	0.0177	0.185	CbGpPWpGaD
Olopatadine—S100A1—skin of body—systemic scleroderma	0.0171	0.051	CbGeAlD
Olopatadine—S100A13—connective tissue—systemic scleroderma	0.0168	0.0501	CbGeAlD
Olopatadine—S100A12—connective tissue—systemic scleroderma	0.0166	0.0495	CbGeAlD
Olopatadine—S100B—connective tissue—systemic scleroderma	0.0164	0.0488	CbGeAlD
Olopatadine—S100A13—smooth muscle tissue—systemic scleroderma	0.0154	0.0459	CbGeAlD
Olopatadine—S100A13—skin of body—systemic scleroderma	0.0152	0.0453	CbGeAlD
Olopatadine—S100B—skin of body—systemic scleroderma	0.0148	0.0441	CbGeAlD
Olopatadine—S100A2—tendon—systemic scleroderma	0.0141	0.0422	CbGeAlD
Olopatadine—S100A1—digestive system—systemic scleroderma	0.0137	0.0408	CbGeAlD
Olopatadine—S100A1—tendon—systemic scleroderma	0.013	0.0388	CbGeAlD
Olopatadine—S100A2—lung—systemic scleroderma	0.0124	0.037	CbGeAlD
Olopatadine—S100A13—digestive system—systemic scleroderma	0.0121	0.0362	CbGeAlD
Olopatadine—S100A12—digestive system—systemic scleroderma	0.012	0.0357	CbGeAlD
Olopatadine—S100A2—Direct p53 effectors—GDF15—systemic scleroderma	0.0112	0.117	CbGpPWpGaD
Olopatadine—S100A13—lung—systemic scleroderma	0.0101	0.0302	CbGeAlD
Olopatadine—S100A12—lung—systemic scleroderma	0.01	0.0298	CbGeAlD
Olopatadine—S100A2—Direct p53 effectors—IRF5—systemic scleroderma	0.00692	0.0724	CbGpPWpGaD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—TNFAIP3—systemic scleroderma	0.00344	0.036	CbGpPWpGaD
Olopatadine—HRH1—connective tissue—systemic scleroderma	0.00336	0.01	CbGeAlD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—TNFAIP3—systemic scleroderma	0.00325	0.034	CbGpPWpGaD
Olopatadine—HRH1—smooth muscle tissue—systemic scleroderma	0.00307	0.00916	CbGeAlD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.00262	0.0274	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—MMP2—systemic scleroderma	0.00257	0.0268	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.00248	0.0259	CbGpPWpGaD
Olopatadine—HRH1—digestive system—systemic scleroderma	0.00242	0.00723	CbGeAlD
Olopatadine—S100A12—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00233	0.0244	CbGpPWpGaD
Olopatadine—HRH1—tendon—systemic scleroderma	0.00231	0.00688	CbGeAlD
Olopatadine—S100B—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00221	0.0231	CbGpPWpGaD
Olopatadine—HRH1—lung—systemic scleroderma	0.00202	0.00604	CbGeAlD
Olopatadine—CYP3A4—digestive system—systemic scleroderma	0.00187	0.00559	CbGeAlD
Olopatadine—Sinusitis—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00227	CcSEcCtD
Olopatadine—Malaise—Leflunomide—systemic scleroderma	0.00129	0.00226	CcSEcCtD
Olopatadine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00128	0.00225	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00128	0.00225	CcSEcCtD
Olopatadine—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00128	0.00224	CcSEcCtD
Olopatadine—Abdominal pain—Mometasone—systemic scleroderma	0.00127	0.00224	CcSEcCtD
Olopatadine—Body temperature increased—Mometasone—systemic scleroderma	0.00127	0.00224	CcSEcCtD
Olopatadine—Discomfort—Azathioprine—systemic scleroderma	0.00127	0.00223	CcSEcCtD
Olopatadine—Mediastinal disorder—Lisinopril—systemic scleroderma	0.00127	0.00223	CcSEcCtD
Olopatadine—Ill-defined disorder—Mycophenolic acid—systemic scleroderma	0.00126	0.00222	CcSEcCtD
Olopatadine—Dyspnoea—Captopril—systemic scleroderma	0.00126	0.00221	CcSEcCtD
Olopatadine—Somnolence—Captopril—systemic scleroderma	0.00126	0.00221	CcSEcCtD
Olopatadine—Cough—Leflunomide—systemic scleroderma	0.00125	0.00219	CcSEcCtD
Olopatadine—Rhinitis—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00217	CcSEcCtD
Olopatadine—Dizziness—Pentoxifylline—systemic scleroderma	0.00123	0.00217	CcSEcCtD
Olopatadine—Hypoaesthesia—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00216	CcSEcCtD
Olopatadine—Malaise—Mycophenolic acid—systemic scleroderma	0.00123	0.00216	CcSEcCtD
Olopatadine—Erythema—Lisinopril—systemic scleroderma	0.00123	0.00216	CcSEcCtD
Olopatadine—Infection—Azathioprine—systemic scleroderma	0.00123	0.00215	CcSEcCtD
Olopatadine—Pharyngitis—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00215	CcSEcCtD
Olopatadine—Fatigue—Captopril—systemic scleroderma	0.00122	0.00214	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00121	0.00212	CcSEcCtD
Olopatadine—Dysgeusia—Lisinopril—systemic scleroderma	0.0012	0.00211	CcSEcCtD
Olopatadine—Discomfort—Leflunomide—systemic scleroderma	0.0012	0.00211	CcSEcCtD
Olopatadine—Skin disorder—Azathioprine—systemic scleroderma	0.0012	0.00211	CcSEcCtD
Olopatadine—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00209	CcSEcCtD
Olopatadine—Dry mouth—Leflunomide—systemic scleroderma	0.00119	0.00209	CcSEcCtD
Olopatadine—Cough—Mycophenolic acid—systemic scleroderma	0.00119	0.00209	CcSEcCtD
Olopatadine—Back pain—Lisinopril—systemic scleroderma	0.00119	0.00208	CcSEcCtD
Olopatadine—Vomiting—Pentoxifylline—systemic scleroderma	0.00119	0.00208	CcSEcCtD
Olopatadine—Muscle spasms—Lisinopril—systemic scleroderma	0.00118	0.00207	CcSEcCtD
Olopatadine—Rash—Pentoxifylline—systemic scleroderma	0.00118	0.00207	CcSEcCtD
Olopatadine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00118	0.00206	CcSEcCtD
Olopatadine—Headache—Pentoxifylline—systemic scleroderma	0.00117	0.00205	CcSEcCtD
Olopatadine—Feeling abnormal—Captopril—systemic scleroderma	0.00116	0.00205	CcSEcCtD
Olopatadine—Infection—Leflunomide—systemic scleroderma	0.00116	0.00203	CcSEcCtD
Olopatadine—Vision blurred—Lisinopril—systemic scleroderma	0.00116	0.00203	CcSEcCtD
Olopatadine—Gastrointestinal pain—Captopril—systemic scleroderma	0.00116	0.00203	CcSEcCtD
Olopatadine—Asthenia—Mometasone—systemic scleroderma	0.00115	0.00203	CcSEcCtD
Olopatadine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00203	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00115	0.00202	CcSEcCtD
Olopatadine—Discomfort—Mycophenolic acid—systemic scleroderma	0.00115	0.00201	CcSEcCtD
Olopatadine—Nervous system disorder—Leflunomide—systemic scleroderma	0.00114	0.00201	CcSEcCtD
Olopatadine—Pruritus—Mometasone—systemic scleroderma	0.00114	0.002	CcSEcCtD
Olopatadine—Ill-defined disorder—Lisinopril—systemic scleroderma	0.00114	0.002	CcSEcCtD
Olopatadine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00113	0.00199	CcSEcCtD
Olopatadine—Skin disorder—Leflunomide—systemic scleroderma	0.00113	0.00199	CcSEcCtD
Olopatadine—Body temperature increased—Captopril—systemic scleroderma	0.00112	0.00196	CcSEcCtD
Olopatadine—Abdominal pain—Captopril—systemic scleroderma	0.00112	0.00196	CcSEcCtD
Olopatadine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00195	CcSEcCtD
Olopatadine—Oedema—Mycophenolic acid—systemic scleroderma	0.00111	0.00195	CcSEcCtD
Olopatadine—Dry skin—Prednisone—systemic scleroderma	0.00111	0.00195	CcSEcCtD
Olopatadine—Nausea—Pentoxifylline—systemic scleroderma	0.00111	0.00195	CcSEcCtD
Olopatadine—Malaise—Lisinopril—systemic scleroderma	0.00111	0.00194	CcSEcCtD
Olopatadine—Infection—Mycophenolic acid—systemic scleroderma	0.0011	0.00194	CcSEcCtD
Olopatadine—Diarrhoea—Mometasone—systemic scleroderma	0.0011	0.00193	CcSEcCtD
Olopatadine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00109	0.00192	CcSEcCtD
Olopatadine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00108	0.0019	CcSEcCtD
Olopatadine—Cough—Lisinopril—systemic scleroderma	0.00107	0.00188	CcSEcCtD
Olopatadine—Visual disturbance—Methotrexate—systemic scleroderma	0.00107	0.00187	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00107	0.00187	CcSEcCtD
Olopatadine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00185	CcSEcCtD
Olopatadine—Back pain—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00183	CcSEcCtD
Olopatadine—Dyspnoea—Leflunomide—systemic scleroderma	0.00104	0.00182	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00104	0.00182	CcSEcCtD
Olopatadine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00182	CcSEcCtD
Olopatadine—Discomfort—Lisinopril—systemic scleroderma	0.00103	0.00181	CcSEcCtD
Olopatadine—Vomiting—Mometasone—systemic scleroderma	0.00102	0.0018	CcSEcCtD
Olopatadine—Dry mouth—Lisinopril—systemic scleroderma	0.00102	0.00179	CcSEcCtD
Olopatadine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00102	0.00179	CcSEcCtD
Olopatadine—Rash—Mometasone—systemic scleroderma	0.00101	0.00178	CcSEcCtD
Olopatadine—Asthenia—Captopril—systemic scleroderma	0.00101	0.00178	CcSEcCtD
Olopatadine—Dermatitis—Mometasone—systemic scleroderma	0.00101	0.00178	CcSEcCtD
Olopatadine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00101	0.00177	CcSEcCtD
Olopatadine—Headache—Mometasone—systemic scleroderma	0.00101	0.00177	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00101	0.00177	CcSEcCtD
Olopatadine—Fatigue—Leflunomide—systemic scleroderma	0.001	0.00176	CcSEcCtD
Olopatadine—Oedema—Lisinopril—systemic scleroderma	0.001	0.00176	CcSEcCtD
Olopatadine—Pruritus—Captopril—systemic scleroderma	0.001	0.00176	CcSEcCtD
Olopatadine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000997	0.00175	CcSEcCtD
Olopatadine—Pain—Leflunomide—systemic scleroderma	0.000996	0.00175	CcSEcCtD
Olopatadine—Infection—Lisinopril—systemic scleroderma	0.000995	0.00175	CcSEcCtD
Olopatadine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000991	0.00174	CcSEcCtD
Olopatadine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000988	0.00174	CcSEcCtD
Olopatadine—Body temperature increased—Azathioprine—systemic scleroderma	0.000975	0.00171	CcSEcCtD
Olopatadine—Abdominal pain—Azathioprine—systemic scleroderma	0.000975	0.00171	CcSEcCtD
Olopatadine—Skin disorder—Lisinopril—systemic scleroderma	0.000972	0.00171	CcSEcCtD
Olopatadine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000969	0.0017	CcSEcCtD
Olopatadine—Diarrhoea—Captopril—systemic scleroderma	0.000967	0.0017	CcSEcCtD
Olopatadine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00096	0.00169	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00096	0.00169	CcSEcCtD
Olopatadine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000958	0.00168	CcSEcCtD
Olopatadine—Nausea—Mometasone—systemic scleroderma	0.000956	0.00168	CcSEcCtD
Olopatadine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000953	0.00167	CcSEcCtD
Olopatadine—Weight increased—Prednisone—systemic scleroderma	0.000952	0.00167	CcSEcCtD
Olopatadine—Pain—Mycophenolic acid—systemic scleroderma	0.00095	0.00167	CcSEcCtD
Olopatadine—Cough—Mycophenolate mofetil—systemic scleroderma	0.000938	0.00165	CcSEcCtD
Olopatadine—Dizziness—Captopril—systemic scleroderma	0.000935	0.00164	CcSEcCtD
Olopatadine—Depression—Prednisone—systemic scleroderma	0.00093	0.00163	CcSEcCtD
Olopatadine—Abdominal pain—Leflunomide—systemic scleroderma	0.000921	0.00162	CcSEcCtD
Olopatadine—Body temperature increased—Leflunomide—systemic scleroderma	0.000921	0.00162	CcSEcCtD
Olopatadine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000916	0.00161	CcSEcCtD
Olopatadine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000909	0.0016	CcSEcCtD
Olopatadine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000909	0.0016	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000909	0.0016	CcSEcCtD
Olopatadine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000904	0.00159	CcSEcCtD
Olopatadine—Vomiting—Captopril—systemic scleroderma	0.000899	0.00158	CcSEcCtD
Olopatadine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000895	0.00157	CcSEcCtD
Olopatadine—Dyspnoea—Lisinopril—systemic scleroderma	0.000893	0.00157	CcSEcCtD
Olopatadine—Rash—Captopril—systemic scleroderma	0.000891	0.00157	CcSEcCtD
Olopatadine—Dermatitis—Captopril—systemic scleroderma	0.000891	0.00156	CcSEcCtD
Olopatadine—Somnolence—Lisinopril—systemic scleroderma	0.00089	0.00156	CcSEcCtD
Olopatadine—Headache—Captopril—systemic scleroderma	0.000886	0.00156	CcSEcCtD
Olopatadine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000879	0.00154	CcSEcCtD
Olopatadine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000879	0.00154	CcSEcCtD
Olopatadine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000877	0.00154	CcSEcCtD
Olopatadine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000871	0.00153	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000864	0.00152	CcSEcCtD
Olopatadine—Fatigue—Lisinopril—systemic scleroderma	0.000863	0.00152	CcSEcCtD
Olopatadine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00086	0.00151	CcSEcCtD
Olopatadine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000858	0.00151	CcSEcCtD
Olopatadine—Pain—Lisinopril—systemic scleroderma	0.000856	0.0015	CcSEcCtD
Olopatadine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000852	0.0015	CcSEcCtD
Olopatadine—Diarrhoea—Azathioprine—systemic scleroderma	0.000844	0.00148	CcSEcCtD
Olopatadine—Nausea—Captopril—systemic scleroderma	0.00084	0.00148	CcSEcCtD
Olopatadine—Asthenia—Leflunomide—systemic scleroderma	0.000836	0.00147	CcSEcCtD
Olopatadine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000825	0.00145	CcSEcCtD
Olopatadine—Pruritus—Leflunomide—systemic scleroderma	0.000824	0.00145	CcSEcCtD
Olopatadine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000819	0.00144	CcSEcCtD
Olopatadine—Dizziness—Azathioprine—systemic scleroderma	0.000816	0.00143	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000812	0.00143	CcSEcCtD
Olopatadine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000797	0.0014	CcSEcCtD
Olopatadine—Diarrhoea—Leflunomide—systemic scleroderma	0.000797	0.0014	CcSEcCtD
Olopatadine—Body temperature increased—Lisinopril—systemic scleroderma	0.000791	0.00139	CcSEcCtD
Olopatadine—Abdominal pain—Lisinopril—systemic scleroderma	0.000791	0.00139	CcSEcCtD
Olopatadine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000786	0.00138	CcSEcCtD
Olopatadine—Vomiting—Azathioprine—systemic scleroderma	0.000784	0.00138	CcSEcCtD
Olopatadine—Eye disorder—Prednisone—systemic scleroderma	0.000782	0.00137	CcSEcCtD
Olopatadine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000782	0.00137	CcSEcCtD
Olopatadine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00078	0.00137	CcSEcCtD
Olopatadine—Infestation—Methotrexate—systemic scleroderma	0.000779	0.00137	CcSEcCtD
Olopatadine—Infestation NOS—Methotrexate—systemic scleroderma	0.000779	0.00137	CcSEcCtD
Olopatadine—Rash—Azathioprine—systemic scleroderma	0.000778	0.00137	CcSEcCtD
Olopatadine—Dermatitis—Azathioprine—systemic scleroderma	0.000777	0.00137	CcSEcCtD
Olopatadine—Depression—Methotrexate—systemic scleroderma	0.000777	0.00136	CcSEcCtD
Olopatadine—Headache—Azathioprine—systemic scleroderma	0.000773	0.00136	CcSEcCtD
Olopatadine—Dizziness—Leflunomide—systemic scleroderma	0.00077	0.00135	CcSEcCtD
Olopatadine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00076	0.00134	CcSEcCtD
Olopatadine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000757	0.00133	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000757	0.00133	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—CD247—systemic scleroderma	0.000756	0.00791	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—ITGAM—systemic scleroderma	0.000756	0.00791	CbGpPWpGaD
Olopatadine—Immune system disorder—Prednisone—systemic scleroderma	0.000756	0.00133	CcSEcCtD
Olopatadine—Pain—Mycophenolate mofetil—systemic scleroderma	0.00075	0.00132	CcSEcCtD
Olopatadine—Vomiting—Leflunomide—systemic scleroderma	0.000741	0.0013	CcSEcCtD
Olopatadine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000738	0.0013	CcSEcCtD
Olopatadine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000735	0.00129	CcSEcCtD
Olopatadine—Epistaxis—Methotrexate—systemic scleroderma	0.000735	0.00129	CcSEcCtD
Olopatadine—Rash—Leflunomide—systemic scleroderma	0.000735	0.00129	CcSEcCtD
Olopatadine—Dermatitis—Leflunomide—systemic scleroderma	0.000734	0.00129	CcSEcCtD
Olopatadine—Nausea—Azathioprine—systemic scleroderma	0.000733	0.00129	CcSEcCtD
Olopatadine—Headache—Leflunomide—systemic scleroderma	0.00073	0.00128	CcSEcCtD
Olopatadine—Erythema—Prednisone—systemic scleroderma	0.000729	0.00128	CcSEcCtD
Olopatadine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000723	0.00127	CcSEcCtD
Olopatadine—Asthenia—Lisinopril—systemic scleroderma	0.000718	0.00126	CcSEcCtD
Olopatadine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000717	0.00126	CcSEcCtD
Olopatadine—S100B—Innate Immune System—ITGAM—systemic scleroderma	0.000715	0.00748	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CD247—systemic scleroderma	0.000715	0.00748	CbGpPWpGaD
Olopatadine—Pruritus—Lisinopril—systemic scleroderma	0.000708	0.00124	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—TNFAIP3—systemic scleroderma	0.000708	0.00741	CbGpPWpGaD
Olopatadine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000707	0.00124	CcSEcCtD
Olopatadine—Rash—Mycophenolic acid—systemic scleroderma	0.000701	0.00123	CcSEcCtD
Olopatadine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.0007	0.00123	CcSEcCtD
Olopatadine—Headache—Mycophenolic acid—systemic scleroderma	0.000696	0.00122	CcSEcCtD
Olopatadine—Pharyngitis—Methotrexate—systemic scleroderma	0.000694	0.00122	CcSEcCtD
Olopatadine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000693	0.00122	CcSEcCtD
Olopatadine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000693	0.00122	CcSEcCtD
Olopatadine—Nausea—Leflunomide—systemic scleroderma	0.000692	0.00122	CcSEcCtD
Olopatadine—Vision blurred—Prednisone—systemic scleroderma	0.000687	0.00121	CcSEcCtD
Olopatadine—Diarrhoea—Lisinopril—systemic scleroderma	0.000685	0.0012	CcSEcCtD
Olopatadine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000676	0.00119	CcSEcCtD
Olopatadine—Visual impairment—Methotrexate—systemic scleroderma	0.000674	0.00118	CcSEcCtD
Olopatadine—S100B—Innate Immune System—TNFAIP3—systemic scleroderma	0.000669	0.00701	CbGpPWpGaD
Olopatadine—Dizziness—Lisinopril—systemic scleroderma	0.000662	0.00116	CcSEcCtD
Olopatadine—Nausea—Mycophenolic acid—systemic scleroderma	0.00066	0.00116	CcSEcCtD
Olopatadine—Malaise—Prednisone—systemic scleroderma	0.000657	0.00115	CcSEcCtD
Olopatadine—Eye disorder—Methotrexate—systemic scleroderma	0.000654	0.00115	CcSEcCtD
Olopatadine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000646	0.00114	CcSEcCtD
Olopatadine—Vomiting—Lisinopril—systemic scleroderma	0.000637	0.00112	CcSEcCtD
Olopatadine—Immune system disorder—Methotrexate—systemic scleroderma	0.000632	0.00111	CcSEcCtD
Olopatadine—Rash—Lisinopril—systemic scleroderma	0.000631	0.00111	CcSEcCtD
Olopatadine—Dermatitis—Lisinopril—systemic scleroderma	0.000631	0.00111	CcSEcCtD
Olopatadine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00063	0.00111	CcSEcCtD
Olopatadine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000629	0.00111	CcSEcCtD
Olopatadine—Headache—Lisinopril—systemic scleroderma	0.000627	0.0011	CcSEcCtD
Olopatadine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000621	0.00109	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000616	0.00108	CcSEcCtD
Olopatadine—Discomfort—Prednisone—systemic scleroderma	0.000613	0.00108	CcSEcCtD
Olopatadine—Erythema—Methotrexate—systemic scleroderma	0.000609	0.00107	CcSEcCtD
Olopatadine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.0006	0.00105	CcSEcCtD
Olopatadine—Dysgeusia—Methotrexate—systemic scleroderma	0.000596	0.00105	CcSEcCtD
Olopatadine—Nausea—Lisinopril—systemic scleroderma	0.000595	0.00104	CcSEcCtD
Olopatadine—Oedema—Prednisone—systemic scleroderma	0.000595	0.00104	CcSEcCtD
Olopatadine—Infection—Prednisone—systemic scleroderma	0.000591	0.00104	CcSEcCtD
Olopatadine—Back pain—Methotrexate—systemic scleroderma	0.000589	0.00103	CcSEcCtD
Olopatadine—Nervous system disorder—Prednisone—systemic scleroderma	0.000583	0.00102	CcSEcCtD
Olopatadine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00058	0.00102	CcSEcCtD
Olopatadine—Skin disorder—Prednisone—systemic scleroderma	0.000578	0.00101	CcSEcCtD
Olopatadine—Vision blurred—Methotrexate—systemic scleroderma	0.000574	0.00101	CcSEcCtD
Olopatadine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000565	0.000993	CcSEcCtD
Olopatadine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000558	0.00098	CcSEcCtD
Olopatadine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000553	0.000972	CcSEcCtD
Olopatadine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000553	0.000971	CcSEcCtD
Olopatadine—Headache—Mycophenolate mofetil—systemic scleroderma	0.00055	0.000965	CcSEcCtD
Olopatadine—Malaise—Methotrexate—systemic scleroderma	0.000549	0.000965	CcSEcCtD
Olopatadine—Cough—Methotrexate—systemic scleroderma	0.000531	0.000933	CcSEcCtD
Olopatadine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000521	0.000915	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000515	0.000904	CcSEcCtD
Olopatadine—Fatigue—Prednisone—systemic scleroderma	0.000513	0.000901	CcSEcCtD
Olopatadine—Discomfort—Methotrexate—systemic scleroderma	0.000512	0.0009	CcSEcCtD
Olopatadine—Infection—Methotrexate—systemic scleroderma	0.000494	0.000867	CcSEcCtD
Olopatadine—Feeling abnormal—Prednisone—systemic scleroderma	0.00049	0.000861	CcSEcCtD
Olopatadine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000487	0.000856	CcSEcCtD
Olopatadine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000486	0.000854	CcSEcCtD
Olopatadine—Skin disorder—Methotrexate—systemic scleroderma	0.000483	0.000848	CcSEcCtD
Olopatadine—Body temperature increased—Prednisone—systemic scleroderma	0.00047	0.000826	CcSEcCtD
Olopatadine—Abdominal pain—Prednisone—systemic scleroderma	0.00047	0.000826	CcSEcCtD
Olopatadine—S100A12—Immune System—CSK—systemic scleroderma	0.000468	0.0049	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IRF5—systemic scleroderma	0.000461	0.00482	CbGpPWpGaD
Olopatadine—Dyspnoea—Methotrexate—systemic scleroderma	0.000443	0.000778	CcSEcCtD
Olopatadine—S100B—Immune System—CSK—systemic scleroderma	0.000443	0.00463	CbGpPWpGaD
Olopatadine—Somnolence—Methotrexate—systemic scleroderma	0.000442	0.000776	CcSEcCtD
Olopatadine—S100A12—Immune System—IRF8—systemic scleroderma	0.00044	0.00461	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CD247—systemic scleroderma	0.00044	0.00461	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ITGAM—systemic scleroderma	0.00044	0.00461	CbGpPWpGaD
Olopatadine—Hypersensitivity—Prednisone—systemic scleroderma	0.000438	0.00077	CcSEcCtD
Olopatadine—S100B—Immune System—IRF5—systemic scleroderma	0.000436	0.00456	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000429	0.000754	CcSEcCtD
Olopatadine—Fatigue—Methotrexate—systemic scleroderma	0.000428	0.000753	CcSEcCtD
Olopatadine—Asthenia—Prednisone—systemic scleroderma	0.000427	0.00075	CcSEcCtD
Olopatadine—Pain—Methotrexate—systemic scleroderma	0.000425	0.000747	CcSEcCtD
Olopatadine—Pruritus—Prednisone—systemic scleroderma	0.000421	0.000739	CcSEcCtD
Olopatadine—S100B—Immune System—CD247—systemic scleroderma	0.000416	0.00436	CbGpPWpGaD
Olopatadine—S100B—Immune System—IRF8—systemic scleroderma	0.000416	0.00436	CbGpPWpGaD
Olopatadine—S100B—Immune System—ITGAM—systemic scleroderma	0.000416	0.00436	CbGpPWpGaD
Olopatadine—S100A12—Immune System—TNFAIP3—systemic scleroderma	0.000412	0.00431	CbGpPWpGaD
Olopatadine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000409	0.000719	CcSEcCtD
Olopatadine—S100A12—Immune System—BLK—systemic scleroderma	0.000407	0.00426	CbGpPWpGaD
Olopatadine—Diarrhoea—Prednisone—systemic scleroderma	0.000407	0.000715	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—SMAD7—systemic scleroderma	0.000406	0.00425	CbGpPWpGaD
Olopatadine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000406	0.000714	CcSEcCtD
Olopatadine—Dizziness—Prednisone—systemic scleroderma	0.000393	0.000691	CcSEcCtD
Olopatadine—Body temperature increased—Methotrexate—systemic scleroderma	0.000393	0.00069	CcSEcCtD
Olopatadine—Abdominal pain—Methotrexate—systemic scleroderma	0.000393	0.00069	CcSEcCtD
Olopatadine—S100B—Immune System—TNFAIP3—systemic scleroderma	0.00039	0.00408	CbGpPWpGaD
Olopatadine—S100B—Immune System—BLK—systemic scleroderma	0.000385	0.00403	CbGpPWpGaD
Olopatadine—Vomiting—Prednisone—systemic scleroderma	0.000378	0.000664	CcSEcCtD
Olopatadine—Rash—Prednisone—systemic scleroderma	0.000375	0.000659	CcSEcCtD
Olopatadine—Dermatitis—Prednisone—systemic scleroderma	0.000375	0.000658	CcSEcCtD
Olopatadine—Headache—Prednisone—systemic scleroderma	0.000372	0.000654	CcSEcCtD
Olopatadine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000366	0.000643	CcSEcCtD
Olopatadine—Asthenia—Methotrexate—systemic scleroderma	0.000357	0.000626	CcSEcCtD
Olopatadine—Nausea—Prednisone—systemic scleroderma	0.000353	0.000621	CcSEcCtD
Olopatadine—Pruritus—Methotrexate—systemic scleroderma	0.000352	0.000618	CcSEcCtD
Olopatadine—Diarrhoea—Methotrexate—systemic scleroderma	0.00034	0.000597	CcSEcCtD
Olopatadine—S100A12—Immune System—CTLA4—systemic scleroderma	0.000334	0.00349	CbGpPWpGaD
Olopatadine—Dizziness—Methotrexate—systemic scleroderma	0.000329	0.000577	CcSEcCtD
Olopatadine—Vomiting—Methotrexate—systemic scleroderma	0.000316	0.000555	CcSEcCtD
Olopatadine—S100B—Immune System—CTLA4—systemic scleroderma	0.000316	0.0033	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—RHOB—systemic scleroderma	0.000314	0.00329	CbGpPWpGaD
Olopatadine—Rash—Methotrexate—systemic scleroderma	0.000313	0.00055	CcSEcCtD
Olopatadine—Dermatitis—Methotrexate—systemic scleroderma	0.000313	0.00055	CcSEcCtD
Olopatadine—Headache—Methotrexate—systemic scleroderma	0.000311	0.000547	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—HSPG2—systemic scleroderma	0.000296	0.0031	CbGpPWpGaD
Olopatadine—Nausea—Methotrexate—systemic scleroderma	0.000295	0.000519	CcSEcCtD
Olopatadine—HRH1—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000293	0.00307	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CSK—systemic scleroderma	0.000286	0.003	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HLA-DQB1—systemic scleroderma	0.000275	0.00288	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000262	0.00274	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL1A—systemic scleroderma	0.000261	0.00273	CbGpPWpGaD
Olopatadine—S100B—Immune System—HLA-DQB1—systemic scleroderma	0.00026	0.00272	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CD40LG—systemic scleroderma	0.00026	0.00272	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL1A—systemic scleroderma	0.000247	0.00258	CbGpPWpGaD
Olopatadine—S100B—Immune System—CD40LG—systemic scleroderma	0.000245	0.00257	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000194	0.00203	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000164	0.00171	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EDN1—systemic scleroderma	0.000161	0.00168	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—RHOB—systemic scleroderma	0.000149	0.00156	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—EDN1—systemic scleroderma	0.000148	0.00155	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL1B—systemic scleroderma	0.000136	0.00142	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000133	0.00139	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL1B—systemic scleroderma	0.000129	0.00135	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SMAD7—systemic scleroderma	0.000114	0.00119	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCL2—systemic scleroderma	0.00011	0.00115	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CCL2—systemic scleroderma	0.000101	0.00106	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NOS3—systemic scleroderma	9.78e-05	0.00102	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—RHOB—systemic scleroderma	8.78e-05	0.000919	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—EDN1—systemic scleroderma	8.36e-05	0.000874	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HSPG2—systemic scleroderma	8.28e-05	0.000866	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CSK—systemic scleroderma	8e-05	0.000837	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MMP9—systemic scleroderma	7.85e-05	0.000821	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—EDN1—systemic scleroderma	7.59e-05	0.000794	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TGFB1—systemic scleroderma	6.47e-05	0.000677	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCL2—systemic scleroderma	5.19e-05	0.000543	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EDN1—systemic scleroderma	4.48e-05	0.000469	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HSPG2—systemic scleroderma	3.85e-05	0.000402	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL2—systemic scleroderma	3.06e-05	0.000321	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.92e-05	0.000305	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NOS3—systemic scleroderma	2.73e-05	0.000286	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MMP9—systemic scleroderma	2.19e-05	0.000229	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TGFB1—systemic scleroderma	1.81e-05	0.000189	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.27e-05	0.000133	CbGpPWpGaD
